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Introduction
Glycogenic hepatopathy is an acquired 
glycogen storage disease seen in type 1 
diabetes, particularly those that are not well 
controlled.
1-3
 It causes elevated transaminase 
levels, hepatomegaly, and abdominal pain. It 
is less recognized than non-alcoholic steato-
hepatitis (NASH) which occurs more 
commonly in type 2 diabetes with metabolic 
syndrome, but is an important diagnosis to 
consider in the appropriate clinical setting. 
 
Case Report 
A 25-year-old white female presented to 
the emergency department due to bilateral 
flank pain. The pain was present for two 
days and was progressing. It was stabbing in 
nature and did not radiate. The patient had 
associated nausea and vomiting. She also 
noted that the pain was similar to symptoms 
she had one month prior when she was 
treated for pyelonephritis.   
The patient’s past medical history was 
significant for uncontrolled type 1 diabetes 
mellitus diagnosed at age 12, hypo-
thyroidism, and chronically elevated 
transaminase levels of undefined etiology.  
Additionally, she recently was treated with 
ceftriaxone and ciprofloxacin for pyelo-
nephritis. Her medications included glargine 
insulin, insulins aspart, and levothyroxine.  
She reported smoking one-half pack of 
cigarettes per day, occasional marijuana use, 
and rare alcohol use. She had no knowledge 
of any family history of liver disease. Her 
review of symptoms was negative, notably 
for dysuria, fever, or chills.   
The patient was afebrile with normal 
vital signs. Her physical exam was benign 
other than mild costovertebral angle 
tenderness bilaterally. Initial labs showed a 
normal complete blood count, electrolytes, 
and kidney function. Transaminase levels 
were abnormal with a serum aspartate 
aminotransferase (AST) level of 870 units/L 
(normal < 37), an alanine aminotransferase 
(ALT) level of 272 units/L (< 65), and an 
alkaline phosphatase level of 262 units/L (< 
136). The international normalized ratio was 
0.9, the bilirubin level was 0.2 mg/dL (0.2 - 
1.2), and albumin concentration was 3.2 
gm/dL (3.4 - 4.5). Urinalysis showed trace 
leukocyte esterase activity, 3+ glucose, and 
1+ bacteria. A urine drug screen was 
negative and acetaminophen and alcohol 
were not detected in the serum. Hemoglobin 
A1c was 11.0%. 
Computed tomography (CT) revealed an 
enlarged liver with attenuation measured at 
82 Hounsfield units (HU; normal for the 
liver is 40 - 60; Figure 1). Based on imaging 
results, hemochromatosis, hemosiderosis, or 
other heavy metal deposition was 
considered. Comparison was made to a CT 
scan done eight years previously which had 
similar findings and recommendations.   
Review of the patient’s prior hospital-
izations revealed elevated transaminase 
levels dating back 11 years. Serologies for
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Figure 1. CT of the abdomen. The liver is 
enlarged and has increased attenuation at 82 
Hounsfield units. 
 
human immunodeficiency virus and viral 
hepatitis were negative over this time frame, 
but no other workup had been done. During 
the current hospitalization, the transaminase 
levels trended up over the first several days 
and a workup was initiated  to determine the  
cause of the elevation with the following 
results: ferritin level, 78 ng/ml (normal 7 - 
283), percent saturation, 17% (11 - 46), total 
iron binding capacity, 322 mcg/dl (250 - 
450), alpha-1-antitrypsin level, 94 mg/dl (90 
- 200), ceruloplasmin level 20.7 mg/dl, (16 - 
45), and absence of anti-nuclear, anti-
smooth muscle, tissue transglutaminase, and 
endomysial antibodies.   
The patient’s transaminase levels peaked 
on day four of hospitalization with an AST 
level of 2,386 units/L and ALT level of 784 
units/L. This was the highest they had been 
at any point in the past. A liver biopsy 
(Figure 2) showed pale cytoplasm on H&E 
stain, no evidence of fibrosis on trichrome 
stain, markedly positive glycogen staining 
on a periodic acid-Schiff stain (PAS), and 
washout of the PAS stain after addition of 
diastase (an enzyme that digests pure 
glycogen). These findings were consistent 
with glycogenic hepatopathy. 
 
 
 
Figure 2. (a) H&E shows pale cytoplasm. (b) Trichrome shows no fibrosis. (c) PAS is positive 
for glycogen. (d) PAS washed out after diastase. 
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Pathophysiology 
Glycogenic hepatopathy (GH) is 
characterized by abnormal glycogen 
accumulation in the liver. It is an acquired 
disease seen in type 1 diabetes, generally 
patients with poor glycemic control.
1-3
 It 
originally was described by Mauriac in1930, 
after the discovery of insulin therapy for 
type 1 diabetes.
4
 In children, it is a 
syndrome of hepatomegaly, growth impair-
ment, and cushingoid features. In adults, it is 
seen as isolated liver disease without the 
other syndromic features.
3
 
The classic presentation of GH is a triad 
of hepatomegaly, abdominal pain, and 
elevated serum transaminases, but not all of 
these features are required. CT scanning 
generally shows increased liver attenuation.
5
 
Definitive diagnosis is made by biopsy 
which shows glycogen accumulation within 
hepatocytes. Generally, fibrosis is minimal.   
The glycogen accumulation seen in GH 
is dependent on high levels of both serum 
glucose and insulin at different times.
1,3 
 
High serum glucose levels allow passive 
diffusion of glucose into hepatocytes where 
glucose is converted to glucose-1-phosphate 
by glucokinase and is trapped in the cell.  
Glucose-1-phosphate is converted to glyco-
gen by glycogen synthase. Glycogen 
synthase is activated by dephosphorylation 
by glycogen synthase phosphatase. The 
concentration of this enzyme is maintained 
by insulin and its activity depends on 
glucose. In patients with poorly controlled 
type 1 diabetes who administer a large 
insulin bolus, hepatocytes will have a large 
amount of glucose-1-phosphate which will 
be converted to glycogen due to the activity 
of glycogen synthase. Glycogenic hepato-
pathy does not occur in all patients with 
poorly controlled type 1 diabetes. The 
development of GH is dependent on defects 
in regulatory proteins in susceptible patients 
(type 1 diabetes), which are clinically 
insignificant in the rest of the population.
3
   
Treatment and Prognosis 
Treatment of GH is limited to more 
rigorous blood glucose control. Tight 
management of glucose and insulin levels 
can lead to complete resolution of the 
clinical, laboratory, and histologic find-
ings.
6-8
 Glycogenic hepatopathy rarely 
progresses to fibrosis. In the largest case 
series investigating histology, 2 of 14 
patients had only mild fibrosis, while the 
remaining 12 patients had none.
9
 This 
contrasts with NASH which is seen more 
commonly in type 2 diabetes with metabolic 
syndrome and has a much higher rate of 
fibrosis and cirrhosis (37% of patients had 
cirrhosis in one study).
10 
 
Discussion 
Some interesting aspects of GH are 
illustrated by this case. First, after 
admission, the transaminase levels trended 
up for the first four days. This may have 
been iatrogenic as she was given high doses 
of insulin to control her blood sugars. If true, 
it demonstrates the importance of high 
insulin levels for progression of this disease 
and may illustrate why GH was not 
described until after the discovery of insulin 
therapy. Additionally, this patient was 
known to have elevated transaminase levels 
for years, but on liver biopsy had no fibrosis, 
illustrating the typical lack of progression to 
fibrosis and cirrhosis in GH.   
Our patient was informed that improve-
ment in the control of her diabetes would 
reverse her liver disease. Three months after 
discharge, her hemoglobin A1c was 10.3%, 
down from 11.0% when she was 
hospitalized. Six months after discharge, her 
AST and ALT levels were 116 units/L and 
87 units/L respectively, much lower than 
during her hospitalization.   
 
Conclusion 
Glycogenic hepatopathy is an acquired 
disorder of glycogen accumulation within 
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hepatocytes seen exclusively in persons with 
poorly controlled type 1 diabetes, typically 
presenting as elevated transaminase levels, 
hepatomegaly, and abdominal pain. In 
contrast to NASH, GH less commonly 
progresses to fibrosis and cirrhosis.  
Definitive diagnosis is made by liver biopsy, 
but an empiric trial of improved glucose 
control can be considered prior to biopsy in 
suspected cases.  Treatment of GH is limited 
to improving glycemic control.   
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